OLMA - NASDAQ
Olema Pharmaceuticals, Inc.
$10.51
-1.7%Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
At a Glance
Live SnapshotOlema Pharmaceuticals, Inc. Management Team
Dr. David C. Myles Ph.D.
Chief Discovery & Non-Clinical Development Officer
Compensation
$200,000
Ms. Shawnte M. Mitchell J.D.
Chief Legal Officer & Corporate Secretary
Dr. Naseem Zojwalla M.D.
Chief Medical Officer
Compensation
$777,970
Mr. Shane William Charles Kovacs M.B.A.
Chief Operating & Financial Officer
Compensation
$845,370
Dr. Sean P. Bohen M.D., Ph.D.
President, Chief Executive Officer & Director
Compensation
$1,120,036
Ms. Julie Dexter
Senior Vice President & Head of People
Ms. Courtney O'Konek
Vice President of Corporate Communications
Ms. Sasha Austin CPA
Vice President of Finance & Controller
Olema Pharmaceuticals, Inc. Insider Positioning
During the last 12 months, insiders have sold $7.21M worth of OLMA shares, with no buying activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
254.7K
7.04M
-7.0M
-$7.04M
6-9 Months
0
0.00
20.0K
163.70K
-164K
-$164K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
Kovacs Shane William Charles
Officer: Ch. Operating & Financial Off.
$2.98M
Myles David C.
Officer: Ch. Discov. & Non-Clin Dev Off
$1.80M
Mitchell Shawnte
Officer: Chief Legal Officer
$946K
Clark Ian T
Director
$862K
Harmon Cyrus
Director
$616K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $7.21M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
OLMA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | April 29, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 28, 2025 | April 28, 2025 | 2025 | |
DEF 14A DEF 14A 2023 N/A | April 26, 2024 | December 31, 2023 | 2023 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 15, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 28, 2022 | June 16, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 27, 2021 | June 08, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.